Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
Open Access
- 31 May 2012
- journal article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 18 (5), 773-779
- https://doi.org/10.1016/j.bbmt.2011.10.044
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation RegistryTransplantation and Cellular Therapy, 2011
- Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantationLeukemia & Lymphoma, 2011
- Multiple myeloma: 2011 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2010
- Integrating Novel Therapies in the Transplant ParadigmThe Cancer Journal, 2009
- Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myelomaLeukemia & Lymphoma, 2009
- High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing countryBone Marrow Transplantation, 2008
- Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaBone Marrow Transplantation, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006
- High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocolBone Marrow Transplantation, 2006
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998